Research Division Biochemical Engineering, Institute of Chemical, Environmental and Bioscience Engineering, TU Wien, Vienna, Austria.
Sciotec Diagnostics Technologies GmbH, Ziegelfeldstr. 3, 3430, Tulln, Austria.
BMC Biotechnol. 2018 May 29;18(1):30. doi: 10.1186/s12896-018-0443-0.
Celiac disease (CD) is one of the most common food-related chronic disorders. It is mediated by the dietary consumption of prolamins, which are storage proteins of different grains. So far, no therapy exists and patients are bound to maintain a lifelong diet to avoid symptoms and long-term complications. To support those patients we developed a tandem single chain Fragment variable (tscFv) acting as a neutralizing agent against prolamins. We recombinantly produced this molecule in E. coli, but mainly obtained misfolded product aggregates, so-called inclusion bodies, independent of the cultivation strategy we applied.
In this study, we introduce this novel tscFv against CD and present our strategy of obtaining active product from inclusion bodies. The refolded tscFv shows binding capabilities towards all tested CD-triggering grains. Compared to a standard polyclonal anti-PT-gliadin-IgY, the tscFv displays a slightly reduced affinity towards digested gliadin, but an additional affinity towards prolamins of barley.
The high binding specificity of tscFv towards prolamin-containing grains makes this novel molecule a valuable candidate to support patients suffering from CD in the future.
乳糜泻(CD)是最常见的与食物有关的慢性疾病之一。它是由食用醇溶蛋白引起的,醇溶蛋白是不同谷物的储存蛋白。到目前为止,还没有治疗方法,患者必须终生坚持饮食,以避免出现症状和长期并发症。为了支持这些患者,我们开发了一种串联单链 Fragment variable(tscFv),作为针对醇溶蛋白的中和剂。我们在大肠杆菌中重组生产了这种分子,但主要获得了错误折叠的产物聚集体,即所谓的包涵体,这与我们应用的培养策略无关。
在本研究中,我们介绍了这种针对 CD 的新型 tscFv,并提出了从包涵体中获得活性产物的策略。复性的 tscFv 显示出对所有测试的触发 CD 的谷物具有结合能力。与标准的多克隆抗 PT-麦醇溶蛋白 IgY 相比,tscFv 对消化麦醇溶蛋白的亲和力略有降低,但对大麦醇溶蛋白的亲和力增加。
tscFv 对含醇溶蛋白谷物的高结合特异性使这种新型分子成为未来支持 CD 患者的有价值的候选物。